B. Roatt

Therapeutic efficacy of a novel immunotherapeutic formulation, combining a multi-epitope chimeric protein and Amphotericin B, in murine L. infantum infection.
20260 citationsauthor #15
A new chimeric protein composed by T-cell epitopes from peroxidoxin and pyridoxal kinase proteins is protective against visceral leishmaniasis.
20250 citationsauthor #18
Synthetic peptides derived from hypothetical proteins as potential antigens for the diagnosis of canine visceral leishmaniasis and tegumentary leishmaniasis.
20252 citationsauthor #16
Potential immunoprophylactic use of a multi-epitope protein of CD4+ and CD8+ T cells against visceral leishmaniasis in Balb/c mice.
20251 citationsauthor #17
Immunotherapeutics Combining a Recombinant Chimeric Protein, Monophosphoryl Lipid A, and Miltefosine Against Visceral Leishmaniasis
20250 citationsauthor #16
Influence of a hyperglycaemic diet on Trypanosoma cruzi infection in mice model
20250 citationsauthor #5
Treatment using vanillin-derived synthetic molecules incorporated into polymeric micelles is effective against infection caused by Leishmania amazonensis species.
20242 citationsauthor #20
Preclinical evaluation of immunogenicity and protective efficacy of a recombinant chimeric protein vaccine against visceral leishmaniasis
20240 citationsauthor #20
Synthetic Peptides Selected by Immunoinformatics as Potential Tools for the Specific Diagnosis of Canine Visceral Leishmaniasis
20244 citationsauthor #11
Immunotherapy Combining Mimotopes Selected by Phage Display Plus Amphotericin B Is Effective for Treatment Against Visceral Leishmaniasis
20241 citationsauthor #15
CD4+ and CD8+ T-cell multi-epitope chimeric protein associated with an MPLA adjuvant induce protective efficacy and long-term immunological memory for the immunoprophylaxis of American Tegumentary Leishmaniasis.
20241 citationsauthor #4
New synthetic molecules incorporated into polymeric micelles used for treatment against visceral leishmaniasis.
20241 citationsauthor #19
Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis
20231 citationsauthor #18
Recombinant endonuclease III protein from Leishmania infantum associated with Th1-type adjuvants is immunogenic and induces protection against visceral leishmaniasis.
20233 citationsauthor #19
The association between rLiHyp1 protein plus adjuvant and amphotericin B is an effective immunotherapy against visceral leishmaniasis in mice.
20237 citationsauthor #14
Efficacy of an Immunotherapy Combining Immunogenic Chimeric Protein Plus Adjuvant and Amphotericin B against Murine Visceral Leishmaniasis
20239 citationsauthor #16
Exogenous surfactant reduces inflammation and redox imbalance in rats under prone or supine mechanical ventilation
20232 citationsauthor #7
Exploring drug repositioning for leishmaniasis treatment: Ivermectin plus polymeric micelles induce immunological response and protection against tegumentary leishmaniasis.
202310 citationsauthor #16
The Use of an Adjuvant System Improves Innate and Adaptive Immune Response When Associated with a Leishmania (Viannia) braziliensis Antigen in a Vaccine Candidate against L. (Leishmania) infantum Infection
20235 citationsauthor #7
Immunoproteomics approach for the discovery of antigens applied to the diagnosis of canine visceral leishmaniasis.
20234 citationsauthor #18
Immunotherapy Using Immunogenic Mimotopes Selected by Phage Display plus Amphotericin B Inducing a Therapeutic Response in Mice Infected with Leishmania amazonensis
20234 citationsauthor #16
A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against Leishmania infantum Infection
202223 citationsauthor #17
Performance of the Wondfo 2019-nCoV antigen test using self-collected nasal versus professional-collected nasopharyngeal swabs in symptomatic SARS-CoV-2 infection
20225 citationsauthor #2
Replacement of Leishmania (Leishmania) infantum Populations in an Endemic Focus of Visceral Leishmaniasis in Brazil
20222 citationsauthor #2
Development of an immunogen containing CD4+/CD8+ T-cell epitopes for the prophylaxis of tegumentary leishmaniasis
20225 citationsauthor #4
A recombinant Leishmania amastigote-specific protein, rLiHyG, with adjuvants, protects against infection with Leishmania infantum.
202211 citationsauthor #18
Leishmania LiHyC protein is immunogenic and induces protection against visceral leishmaniasis
20227 citationsauthor #17
LBMPL Vaccine Therapy Induces Progressive Organization of the Spleen Microarchitecture, Improved Th1 Adaptative Immune Response and Control of Parasitism in Leishmania infantum Naturally Infected Dogs
20221 citationsauthor #1
Immunoprophylaxis using polypeptide chimera vaccines plus adjuvant system promote Th1 response controlling the spleen parasitism in hamster model of visceral leishmaniasis.
20222 citationsauthor #10
CD4+ T-lymphocytes from asymptomatic dogs infected with Leishmania infantum are able to activate macrophages for higher leishmanicidal ability in an in vitro co-culture experiment.
20223 citationsauthor #4
Recombinant guanosine-5'-triphosphate (GTP)-binding protein associated with Poloxamer 407-based polymeric micelles protects against Leishmania infantum infection.
20225 citationsauthor #19
Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary study.
20218 citationsauthor #18
Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis.
20216 citationsauthor #11
Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis
202114 citationsauthor #19
IL-10 receptor blockade controls the in vitro infectivity of Leishmania infantum and promotes a Th1 activation in PBMC of dogs with visceral leishmaniasis.
202112 citationsauthor #9
A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice.
202120 citationsauthor #5
Establishment of monoclonal antibodies to evaluate the cellular immunity in a hamster model of L infantum infection
20214 citationsauthor #6
Leishmania eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against Leishmania infantum infection.
20219 citationsauthor #20
Heterologous vaccine therapy associated with half course of Miltefosine promote activation of the proinflammatory response with control of splenic parasitism in a hamster model of visceral leishmaniasis
20212 citationsauthor #10
Immunochemotherapy for visceral leishmaniasis: combinatorial action of Miltefosine plus LBSapMPL vaccine improves adaptative Th1 immune response with control of splenic parasitism in experimental hamster model
20215 citationsauthor #9
In vitro and in vivo antileishmanial activity of β-acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis
202110 citationsauthor #15
Chimeric Vaccines Designed by Immunoinformatics-Activated Polyfunctional and Memory T cells that Trigger Protection against Experimental Visceral Leishmaniasis
202033 citationsauthor #8
Histopathological changes in the gastrointestinal tract and systemic alterations triggered by experimental oral infection with Trypanosoma cruzi.
20207 citationsauthor #5
Recent advances and new strategies in Leishmaniasis diagnosis
202047 citationsauthor #5
Leishmania infantum amastin protein incorporated in distinct adjuvant systems induces protection against visceral leishmaniasis.
202017 citationsauthor #17
A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection
202038 citationsauthor #16
Evaluation of the protective efficacy of a Leishmania protein associated with distinct adjuvants against visceral leishmaniasis and in vitro immunogenicity in human cells
20209 citationsauthor #16
Author response for "Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis"
20200 citationsauthor #18
Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis
20201 citationsauthor #16
A clioquinol-containing Pluronic® F127 polymeric micelle system is effective in the treatment of visceral leishmaniasis in a murine model
202027 citationsauthor #21
A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
20209 citationsauthor #19
Liver infusion tryptose (LIT): the best choice for growth, viability, and infectivity of Leishmania infantum parasites
20208 citationsauthor #8
Leishmania infantum pyridoxal kinase evaluated in a recombinant protein and DNA vaccine to protects against visceral leishmaniasis.
20206 citationsauthor #20
Corrigendum to "Leishmania infantum pyridoxal kinase evaluated in a recombinant protein and DNA vaccine to protects against visceral leishmaniasis". Molecular Immunology 124 (2020) 161-171.
20201 citationsauthor #19
Recent advances and new strategies on leishmaniasis treatment
2020185 citationsauthor #1
A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection.
20203 citationsauthor #16
Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
202020 citationsauthor #17
Phase I and II Clinical Trial Comparing the LBSap, Leishmune®, and Leish-Tec® Vaccines against Canine Visceral Leishmaniasis
202010 citationsauthor #2
Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis
202021 citationsauthor #15
Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis
202013 citationsauthor #16
Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis
20207 citationsauthor #18
Canine visceral leishmaniasis biomarkers and their employment in vaccines.
201935 citationsauthor #16
A Pluronic® F127-based polymeric micelle system containing an antileishmanial molecule is immunotherapeutic and effective in the treatment against Leishmania amazonensis infection.
201926 citationsauthor #15
Neutrophil properties in healthy and Leishmania infantum-naturally infected dogs
201917 citationsauthor #5
Immunodiagnosis of human and canine visceral leishmaniasis using recombinant Leishmania infantum Prohibitin protein and a synthetic peptide containing its conformational B-cell epitope.
201917 citationsauthor #11
Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infection.
201922 citationsauthor #17
Synthetic Peptides Elicit Strong Cellular Immunity in Visceral Leishmaniasis Natural Reservoir and Contribute to Long-Lasting Polyfunctional T-Cells in BALB/c Mice
201922 citationsauthor #7
In vivo antileishmanial efficacy of a naphthoquinone derivate incorporated into a Pluronic® F127-based polymeric micelle system against Leishmania amazonensis infection.
201926 citationsauthor #15
Immunization with the HisAK70 DNA Vaccine Induces Resistance against Leishmania Amazonensis Infection in BALB/c Mice
201914 citationsauthor #4
Effect on cellular recruitment and the innate immune response by combining saponin, monophosphoryl lipid-A and Incomplete Freund's Adjuvant with Leishmania (Viannia) braziliensis antigens for a vaccine formulation.
20197 citationsauthor #11
Comparative analysis of real-time PCR assays in the detection of canine visceral leishmaniasis
20189 citationsauthor #6
Cross-protective efficacy of a conserved Leishmania braziliensis recombinant protein as a candidate vaccine against visceral leishmaniasis
20180 citationsauthor #14
Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis.
201836 citationsauthor #10
Vaccination with a CD4+ and CD8+ T‐cell epitopes‐based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis
201832 citationsauthor #15
A Leishmania hypothetical protein‐containing liposome‐based formulation is highly immunogenic and induces protection against visceral leishmaniasis
201819 citationsauthor #9
A Leishmania hypothetical protein applied for the diagnosis and as a serological marker for post-treatment evaluation of tegumentary leishmaniasis patients
20180 citationsauthor #11
Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans.
201814 citationsauthor #12
High-through identification of T cell-specific phage-exposed mimotopes using PBMCs from tegumentary leishmaniasis patients and their use as vaccine candidates against Leishmania amazonensis infection
201814 citationsauthor #17
COMPOSITION VACCINALE POUR PROTECTION CONTRE LA LEISHMANIOSE TÉGUMENTAIRE
20180 citationsauthor #9
Peptide Vaccines for Leishmaniasis
201870 citationsauthor #6
Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice
201721 citationsauthor #10
Performance of Leishmania braziliensis enolase protein for the serodiagnosis of canine and human visceral leishmaniosis.
201711 citationsauthor #12
An ELISA immunoassay employing a conserved Leishmania hypothetical protein for the serodiagnosis of visceral and tegumentary leishmaniasis in dogs and humans.
201729 citationsauthor #10
Probing the efficacy of a heterologous Leishmania/L. Viannia braziliensis recombinant enolase as a candidate vaccine to restrict the development of L. infantum in BALB/c mice.
201716 citationsauthor #11
Leishmania infantum mimotopes and a phage-ELISA assay as tools for a sensitive and specific serodiagnosis of human visceral leishmaniasis.
201727 citationsauthor #9
Selection strategy of phage-displayed immunogens based on an in vitro evaluation of the Th1 response of PBMCs and their potential use as a vaccine against Leishmania infantum infection
201715 citationsauthor #14
A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from Leishmania braziliensis cross-protection against Leishmania amazonensis infection.
201721 citationsauthor #9
Comparative genomics of canine-isolated Leishmania (Leishmania) amazonensis from an endemic focus of visceral leishmaniasis in Governador Valadares, southeastern Brazil
201774 citationsauthor #3
Recombinant prohibitin protein of Leishmania infantum acts as a vaccine candidate and diagnostic marker against visceral leishmaniasis.
201740 citationsauthor #17
Recombinant small glutamine‐rich tetratricopeptide repeat‐containing protein of Leishmania infantum: Potential vaccine and diagnostic application against visceral leishmaniasis
201715 citationsauthor #17
A recombinant fusion protein displaying murine and human MHC class I- and II-specific epitopes protects against Leishmania amazonensis infection.
201727 citationsauthor #9
Impact of dose and surface features on plasmatic and liver concentrations of biodegradable polymeric nanocapsules
201718 citationsauthor #3
A recombinant chimeric protein composed of human and mice‐specific CD4+ and CD8+ T‐cell epitopes protects against visceral leishmaniasis
201745 citationsauthor #7
A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden
201741 citationsauthor #1
Association between mast cells, tissue remodelation and parasite burden in the skin of dogs with visceral leishmaniasis.
20177 citationsauthor #7
Evaluation of a hypothetical protein for serodiagnosis and as a potential marker for post-treatment serological evaluation of tegumentary leishmaniasis patients
201727 citationsauthor #11
Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis.
201651 citationsauthor #5
Cross‐protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis
20165 citationsauthor #6
Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis
201624 citationsauthor #5
A new Leishmania-specific hypothetical protein and its non-described specific B cell conformational epitope applied in the serodiagnosis of canine visceral leishmaniasis
201638 citationsauthor #11

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT